A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

@inproceedings{Vu2015ANC,
  title={A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys},
  author={Minh Diem Vu and Samuel Moser and Camille Delon and Melanie Latzko and Reto Gianotti and Remo L{\"u}oend and Chlo{\'e} Friang and Ramona Murr and Lydia Jasmin Duerner and Tina Weinzierl and Tanja Fauti and Marina Bacac and Oliver Ast and Anne Freimoser-Grundschober and Tea Rodriguez Diaz and J{\"o}rg Zielonka and Erwin van Puijenbroek and Ralf J. Hosse and Peter Bruenker and Ekkehard Moessner and Christian Klein and Pablo Uma{\~n}a and Klaus Strein},
  year={2015}
}
Background & Aim: T-cell bispecific antibodies (TCBs) binding to a target on tumor cells and CD3 on T cells induce potent T-cell mediated killing of cells carrying the target. In contrast to targets like e.g. CD38 or CD138, B-cell maturation antigen (BCMA) is suggested to be only expressed on plasma cells (PCs) and multiple myeloma (MM) PCs. Therefore, a BCMA-TCB should specifically act on these cell types. We report on a new class of BCMA-TCBs designed for effective and convenient therapy of… CONTINUE READING